[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335523-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335523-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-and-immune-correlation-of-ido1-promoter-methylation-in-breast-cancer","Prognostic and immune correlation of IDO1 promoter methylation in breast cancer","","Indoleamine 2,3-dioxygenase 1 (IDO1) promoter methylation is investigated for its biological and clinical relevance in breast cancer, with emphasis on prognosis and antitumor immune regulation. Bioinformatics analyses in the TCGA breast cancer cohort (779 samples) relate IDO1 promoter methylation to survival, tumor immune cell infiltration, immune-related pathways, and immunomodulator expression. In vitro MSP and qPCR assays assess IDO1 promoter methylation and IDO1 expression in the basal subtype, revealing significant hypomethylation associated with higher IDO1 expression, abundant immune infiltration, pathway activation, and improved biomarker potential for predicting immune checkpoint inhibitor response.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-and-immune-correlation-of-ido1-promoter-methylation-in-breast-cancer/335523/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-and-immune-correlation-of-ido1-promoter-methylation-in-breast-cancer/335523.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the study about IDO1 promoter methylation in breast cancer?","Question",{"text":63,"@type":64},"To determine the biological and clinical significance of IDO1 promoter methylation, focusing on its links to survival, prognosis, immune infiltration, immune-related pathways, and immunomodulator expression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What evidence supports the association between IDO1 promoter methylation and immune activity?",{"text":68,"@type":64},"TCGA-based bioinformatics connects methylation status with immune cell infiltration and immune pathway activation, while MSP and qPCR experiments show basal-subtype hypomethylation associated with higher IDO1 expression and increased immunomodulators.",{"name":70,"@type":61,"acceptedAnswer":71},"How do the findings position IDO1 promoter methylation as a biomarker?",{"text":72,"@type":64},"The results indicate that IDO1 promoter methylation regulates IDO1 expression and shapes the tumor microenvironment, supporting its use as a promising biomarker to predict responses to immune checkpoint inhibitors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335523,1790728574,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":4},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPrognostic and immune correlation of IDO1 promoter methylation in breast cancer  \nShirong Ding1,4, Ruozhu Yang2,3,4, Jiahao Meng2,3, Xinyu Guan2,3, Yue Hong2,3, Jiachi Xu2,3, Limeng Qu2,3, Jingfen Ji2,3, Wenjun Yi2,3, Qiongyan Zou2,3􀀍 & Qian Long2,3􀀍  \nIndoleamine 2,3-dioxygenase 1 (IDO1) plays an important role in the initiation and progression of breast cancer. DNA promoter methylation status has the potential to be used as a biomarker for predicting the response to immunotherapy. This study aimed to investigate the biological and clinical significance of IDO1 promoter methylation in breast cancer. We analyzed IDO1 promoter methylation and its relationship with survival, patient prognosis, immune cell infiltration, immunerelated pathways, and the expression of key immunomodulators via bioinformatics methods in The Cancer Genome Atlas (TCGA) breast cancer cohort (779 samples) . Furthermore, the IDO1 promoter methylation status and expression of the IDO1 gene in the basal subtype of breast cancer were investigated in vitro via a methylation-specific PCR (MSP) assay and quantitative polymerase chain reaction (qPCR). The IDO1 promoter was significantly hypomethylated in the basal subtype of breast cancer tissues compared with normal adjacent tissues, and this effect was correlated with high expression of IDO1, resulting in abundant immune cell infiltration, activation of immunerelated pathways, and upregulation of key immunomodulators. The influence of IDO1 promoter hypomethylation on the prognosis of patients with breast cancer was also investigated. The promoter hypomethylation of IDO1 in the basal subtype of breast cancer and its correlation with high expression of IDO1 were also investigated in vitro. Our results showed that IDO1 promoter methylation is  \nvital for regulating its expression, which leads to the development of a tumor microenvironment in breast cancer. IDO1 promoter methylation and expression are associated with prognosis, immune cell infiltration, immune-related pathways, and immunomodulator expression in breast cancer. Our findings provide evidence for the validation of IDO1 promoter methylation as a promising biomarker to predict responses to immune checkpoint inhibitors in patients with breast cancer.  \nKeywords DNA methylation, Epigenetics, Biomarker, IDO1, Breast cancer, Tumor immune microenvironment  \nAbbreviations  \nIDO1 Indoleamine 2,3-dioxygenase 1  \nTCGA The Cancer Genome Atlas  \nCPTAC Clinical Proteome Tumor Analysis Consortium  \nHER2 Human epidermal growth factor receptor 2  \nCTLA4 Cytotoxic T-lymphocyte antigen 4 LAG3 Lymphocyte-activation gene 3  \nPD-1 Programmed cell death protein 1  \nPD-L1 Programmed cell death ligand 1  \nTIL Tumor-infiltrating lymphocytes  \nL-Trp L-tryptophan  \nDCs Dendritic cells  \nTreg Regulatory T cell  \nL-Kyn L-kynurenine  \n1Department of Oncology, the Second Xiangya Hospital of Central South University, Changsha, China.  \n2Department of General Surgery, the Second Xiangya Hospital of Central South University, 139 Middle Renmin Road, Changsha 410011, China. 3Clinical Research Center for Breast Disease in Hunan Province, Changsha 410011, China. 4These authors contributed equally: Shirong Ding and Ruozhu Yang. 􀀍 email: [zqy4311@csu.edu.cn](zqy4311@csu.edu.cn); [dr_longqian@csu.edu.cn](dr_longqian@csu.edu.cn)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nAhR  \nbreast cancer APC  \nPD-L2 TIGHT TNFRSF9  \nAryl hydrocarbon receptor Breast cancer  \nAntigen-presenting cells PD-L1 ligand 2  \nT cell immunoglobulin and ITIM domain  \nTumor necrosis factor receptor superfamily member 9  \nBreast cancer accounts for 31% of all newly diagnosed cancer cases among women in the United States, according to estimates from cancer statistics in 20221, and it is the most prevalent type of cancer in women. Breast cancer is a diverse disease, and on the basis of the gene expression profile ","cbCaisThP2K3VK7T","https://ap.wps.com/l/cbCaisThP2K3VK7T","pdf",7422323,16,"English","# Background and Rationale\n## IDO1 in breast cancer biology\n## Immune checkpoint inhibitors and biomarker need\n# Study Design and Methods\n## TCGA bioinformatics analysis\n## MSP assay and qPCR in basal subtype\n# Key Findings\n## Hypomethylation in basal subtype\n## Correlation with IDO1 expression and immune infiltration\n## Immune pathway activation and immunomodulator upregulation\n# Clinical Implications\n## Prognostic value and biomarker validation","[{\"question\":\"What is the main goal of the study about IDO1 promoter methylation in breast cancer?\",\"answer\":\"To determine the biological and clinical significance of IDO1 promoter methylation, focusing on its links to survival, prognosis, immune infiltration, immune-related pathways, and immunomodulator expression.\"},{\"question\":\"What evidence supports the association between IDO1 promoter methylation and immune activity?\",\"answer\":\"TCGA-based bioinformatics connects methylation status with immune cell infiltration and immune pathway activation, while MSP and qPCR experiments show basal-subtype hypomethylation associated with higher IDO1 expression and increased immunomodulators.\"},{\"question\":\"How do the findings position IDO1 promoter methylation as a biomarker?\",\"answer\":\"The results indicate that IDO1 promoter methylation regulates IDO1 expression and shapes the tumor microenvironment, supporting its use as a promising biomarker to predict responses to immune checkpoint inhibitors.\"}]","Prognostic and immune correlation of IDO1 promoter methylation in breast cancer | PDF",1790011290]